Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

28.07 +0.61 (+2.22%)
Streaming Delayed Price Updated: 12:57 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 171,056
Open 28.09
Bid (Size) 28.08 (1)
Ask (Size) 28.10 (2)
Prev. Close 27.46
Today's Range 27.91 - 28.18
52wk Range 26.32 - 42.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
NASDAQ:GMAB is not too expensive for the growth it is showing.
Via Chartmill

Performance

YTD
-12.58%
-12.58%
1 Month
-8.95%
-8.95%
3 Month
-0.28%
-0.28%
6 Month
-0.78%
-0.78%
1 Year
-31.27%
-31.27%

More News

Read More
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
Via Investor's Business Daily
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Analyst Ratings For Genmab
Via Benzinga
4 Analysts Assess Genmab: What You Need To Know
Via Benzinga
Earnings Outlook For Genmab
Via Benzinga
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Genmab
Via Benzinga
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
What's Going On With Danish Healthcare Firm Genmab Stock?
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB.
Via Chartmill
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
Via Chartmill
Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.